Rhenovia is a biotechnology firm, world leader in biosimulation founded in 2007 by seasoned professionals of the big pharmaceutical industry and renowned academic institutions cumulating over 200 years experience and 800 scientific publications. Headquartered in Mulhouse (France), Rhenovia, as an international team and company, is spreading its partnership business activity in the US with the creation of a fully owned subsidiary in Cambridge (MA) (January 2012) and branches in Germany and Switzerland. As a fully integrated company, Rhenovia is dedicated to global healthcare in the field of central and peripheral nervous system (C&PNS) diseases for an improved quality of life of patients, their families and caregivers. It has recently expanded its core activity by developing innovative solutions
- To PROTECT against prolonged exposure to neurotoxic agents as risk factors for diseases like Alzheimer (chemicals, agrochemicals, or pollutants in the Eco-toxicology environment) and acute exposure (protection of military personnel against chemical weapons and civilians against terrorist threats)
- To PREVENT occurrence of neurodegenerative diseases by nutrition- health and wellness
- To TREAT diseases by
o optimizing the Drug Discovery and Development via its RHEDDOS™ service-partnership offerings to reduce costs, attrition rate and time-to-market
o elaborating individualized drug and active compound delivery with its revolutionary rate controlled transdermal delivery device RHEPATCH™
o developing high performance analytical methods for the identification of drug efficacy biomarkers and side effects alerts
o using its unique Modeling & Simulation platforms RHENOMS™ HIPP and STRI integrating the complexity of neuronal biological systems and multifactorial nature of C&PNS pathologies.
Rhenovia Pharma is intensifying the development of Modeling & Simulation platforms in many fields of applications and therapeutic areas with a recent new focus on rare, orphan and neglected diseases such as Huntington’s disease and muscular dystrophies.
The core business of Rhenovia Pharma is providing services and offering partnership or strategic alliance opportunities to industries as broad as pharma and biotech, agro-food, chemicals and cosmetics as well as to patient foundations, academic institutions, regulatory agencies and governmental organizations. Rhenovia Inc. serves as the commercial branch of Rhenovia Pharma in the US and Rhenovia Development (in preparation in the US) will develop its own pipeline of drug candidates. At present, we are in the process of filing patents for our first compound identified using our biosimulation technology; it is available for out-licensing.